LLY-507
LLY-507 Basic information
- Product Name:
- LLY-507
- Synonyms:
-
- LLY-507
- 5-Cyano-2'-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]-1-piperazinyl]-N-[3-(1-pyrrolidinyl)propyl]-[1,1'-biphenyl]-3-carboxamide
- 5-cyano-2'-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]-1-piperazinyl]-N-[3-(1-pyrrol
- LLY-507(CHEMBL3414623)
- LLY-507; LLY507;LLY 507
- CS-2196
- 5-Cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]-1-piperazinyl}-N-[3-(1-pyrrolidinyl)propyl]-3-biphenylcarboximidic acid
- 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide
- CAS:
- 1793053-37-8
- MF:
- C36H42N6O
- MW:
- 574.76
- Mol File:
- 1793053-37-8.mol
LLY-507 Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- ≥57.5 mg/mL in DMSO; insoluble in H2O; ≥54.7 mg/mL in EtOH
- form
- solid
- color
- White to off-white
LLY-507 Usage And Synthesis
Uses
LLY-507 is a small molecule inhibitor of SMYD2 (lysine N-methyltransferase), preventing p53 lysine methylation in squamous cell carcinoma cells. Shows a >100-fold selective for SMYD2 over 27 other protein methyltransferases (and non-methyltransferase) targets.
Biological Activity
lly-507 is a potent inhibitor of smyd2.smyd2, a lysine methyltransferase, catalyzes the monomethylation of several protein substrates including p53. smyd2 is reported to be overexpressed in a significant percentage of esophageal squamous primary carcinomas, and such overexpression related with poor patient survival.
in vitro
lly-507 has been identified as a cell-active, potent small molecule inhibitor of smyd2. lly-507 was found to be >100-fold selective for smyd2 over a broad range of methyltransferase and non-methyltransferase targets. the crystal structure of smyd2 in complex with lly-507 showed it bound in the substrate peptide binding pocket. lly-507 was active in cells as demonstrated by the reduction of smyd2-induced monomethylation of p53 lys(370) at submicromolar concentrations. furthermore, ms-based proteomics indicated that cellular histone methylation levels were not affected by smyd2 inhibition with lly-507 significantly, and subcellular fractionation studies showed that smyd2 was primarily cytoplasmic, indicating that smyd2 targeted a small subset of histones. moreover, lly-507 was able to inhibit the proliferation of several liver, esophageal, as well as breast cancer cell lines in a dose-dependent manner [1].
IC 50
< 15 nm
References
[1] nguyen h, et al. lly-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase smyd2. j biol chem. 2015 may 29;290(22):13641-13653.
LLY-507Supplier
- Tel
- sales@boylechem.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 0755-0755-66853366 13670046396
- sales@chem-strong.com
- Tel
- 025-58849295 18951903616;
- info@adooq.cn
- Tel
- 021-52996696,15000506266 15000506266
LLY-507(1793053-37-8)Related Product Information
- AZD6738
- SGC707
- MS023
- 2-(2-Chlorophenyl)-4-(3-(diMethylaMino)phenyl)-5-Methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione
- 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
- Enasidenib
- Epacadostat (INCB024360)
- indoleaMine-2,3-dioxygenase inhibitor INCB024360
- 4-BroMo-N-(4-broMophenyl)-3-[[(phenylMethyl)aMino]sulfonyl]benzaMide
- DBeQ